Clinical Trial

Stratagen Quantitative Prostate MRI Platform Pilot Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2026 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions. * What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform? * Can the data collected be used to measure quantitative MRI parameters? Participants will: \- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-20; most recent amendment 2026-03-05.
Status change: Not Yet Recruiting → Recruiting 2025-10-17
Trial Details
NCT Number NCT06985238
Lead Sponsor Stratagen Bio, Inc.
Conditions Prostate Cancer
Enrollment 75 participants
Start Date 2025-09-24
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-06